Head office: +98 21 8854 0521 Saturday to Wednesday, 8:00–17:00 info@meshcutpharmed.com Contact usPartnership
Meshkat Pharmed DistributionMeshkat Pharmed DistributionNationwide distribution of medicines and health products

Featured news: Meshkat Pharmaceutical and Medical Holding invests in technologies to extend human lifespan

Mohsen Mazaheri, owner of the Meshkat Pharmaceutical and Medical Holding, has announced the group’s strategic plan to invest in biotechnology, modern medicine and research related to…

NewsOctober 24, 2026
Featured news: Meshkat Pharmaceutical and Medical Holding invests in technologies to extend human lifespan

Mohsen Mazaheri, owner of the Meshkat Pharmaceutical and Medical Holding, has announced the group’s strategic plan to invest in biotechnology, modern medicine and research related to extending human lifespan, stating that achieving technologies that can meaningfully extend healthy human life has become one of the group’s key areas of investment and development.

Referring to scientific and technological capabilities in cellular, genetic and pharmaceutical fields, Mazaheri said:

“At Meshkat, we consider extending healthy human lifespan and countering the biological processes associated with ageing to be among the important areas of investment in the future of medicine. Our goal is to develop scientific and innovative solutions that, if proven effective and safe, can open new horizons in regenerative medicine and human health.”

Biological research focused on cells, genes and drugs

The owner of the Meshkat Holding went on to describe the group’s research and development in combined cellular, genetic and pharmaceutical approaches:

“One of our areas of focus is studying the biological mechanisms that affect lifespan and identifying methods that can influence the processes associated with ageing. In this effort, preclinical studies, investigation of genetic and cellular mechanisms and the study of factors affecting longevity in animal species and mammals are particularly important.”

He continued:

Understanding genetic factors, cellular repair mechanisms and the biological processes related to ageing can lay the groundwork for a new generation of medical technologies. Our approach in this field is to draw on scientific capabilities and to combine cellular, genetic and pharmaceutical knowledge to explore new ways of extending healthy human life. Mazaheri also stressed that translating laboratory findings into human applications requires rigorous research stages, preclinical evaluation, safety and efficacy assessment and the necessary legal approvals.

A 150-year horizon: a vision for future research

Referring to the long-term vision of this investment, Mazaheri said:

Extending healthy human lifespan to around 150 years is one of the ambitious horizons that may shape part of the direction of our future research. We believe that advances in biotechnology, genetics, cellular medicine and new drugs can create new opportunities to understand the ageing process and to add healthy years to human life.

He added: our approach is not limited to a single technology; it focuses on investigating and developing combined cellular, genetic and pharmaceutical methods. The ultimate goal is to identify and develop solutions that, while extending lifespan, improve quality of life, physical health and independence in older age.

According to him, investment in this field could in future lay the foundation for new capabilities in the pharmaceutical industry, regenerative medicine, cell- and gene-based therapies and technologies related to health and ageing.

Next step: expanding research and scientific evaluation

Highlighting the importance of developing research infrastructure and new health technologies, the owner of the Meshkat Holding announced the group’s plan to expand its research and development activities in longevity, regenerative medicine and biotechnology.

He stated: developing these technologies requires continuous research, careful evaluation of results and collaboration among specialists from different scientific fields. Any move into human clinical studies must also be based on credible scientific evidence, established safety, approval from the competent authorities and compliance with research ethics standards.

Mazaheri concluded that the future of the health industry, beyond treating disease, is moving toward preventing age-related diseases, preserving physical and cognitive abilities and extending healthy lifespan — a path that, in his view, can create new opportunities for investment in advanced medical technologies.

Meshkat and the future of the longevity industry

With its focus on investment in pharmaceuticals, biotechnology and new health technologies, the Meshkat Pharmaceutical and Medical Holding intends to pursue activities related to longevity research and the medicine of the future within its strategic plans.

Extending healthy human lifespan, developing cellular and genetic technologies and harnessing pharmaceutical capabilities to counter the processes associated with ageing are among the areas that may play an important role in transforming the health industry in the years ahead.

Original Persian text: meshcutpharmed.com